Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million during the quarter, compared to analyst estimates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...